Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234832 · ClinicalTrials.gov registry record · Phase 3
A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 10,777
- Enrollment target
NCT00234832: Completed Phase 3 study, sponsored by Abbott.
NCT00234832 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 10,777 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1298% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00234832, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10,777 participants
- Enrollment target
Study Summary
The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
Primary Outcome
For each subject, POE status (with/without an event) and time to first occurrence of a POE using time-to-event analysis were evaluated. All POE confirmed by an independent adjudication committee were included in the analysis.
Interventions
- DRUG Placebo
- DRUG Sibutramine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,777 participants |
| Start Date | 2003-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
What the finished NCT00234832 record still lists
NCT00234832 is an interventional study that assigns participants to a tested intervention. Its 10,777 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1298% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00234832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00234832 about?
NCT00234832 is a clinical study titled "A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients". The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
What is the current status of trial NCT00234832?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10,777 participants. The study started on 2003-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00234832?
The interventions under investigation include: Placebo (DRUG), Sibutramine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00234832?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00234832's enrollment target sits among peer trials
10,777 25th of 2000 higher than 1,976 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06468202 · 10,742 participants · Phase 4
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
- NCT06736951 · 10,890 participants · NA
Modifying the Inpatient Environment to Reduce Delirium in Older Adults
- NCT06081517 · 10,600 participants
Evaluating Disparities in Precision Oncology
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia